SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer.
What the end of affirmative action means to a fourth-year medical student
When the U.S. Supreme Court released its landmark ruling overturning the use of race-conscious college admissions, LaShyra Nolen was on clinical rotation. For Nolen, a